189 terminated. 189 Phase 1, 4 Phase 2.
By phase and status
Follow Healthy: new trials by email Literature Review of Healthy trials Research Report on Healthy
Trials (filtered) newest first · largest first
All 189 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood BI 3031185, Placebo matching BI 3031185, Midazolam - Healthy Phase 1 Terminated 8 2026-07-17 2026-10-06 A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions Tafamidis (Reference), Tafamidis (Test) - Healthy Phase 1 Terminated 24 2026-03-23 2026-06-26 A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults PF-07985631, Placebo - Healthy Phase 1 Terminated 9 2025-12-11 2026-08-18 A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood BI 3009947 (Formulation A), BI 3009947 (Formulation B), Placebo - Healthy Phase 1 Terminated 40 2025-11-21 2026-04-01 A Study of LY4064912 in Healthy Participants and With Overweight or Obesity LY4064912, Placebo - Overweight or Obesity, Healthy Phase 1 Terminated 77 2025-08-28 2026-09-14 A Study to Test How BI 1819479 is Taken up and Processed by the Body [14C]BI 1819479, BI 1819479, BI 1819479 (C-14) - Healthy Phase 1 Terminated 7 2025-08-04 2026-09-30 A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. REM0045392, Placebo - Healthy Phase 1 Terminated 19 2025-03-20 2026-02-04 A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults Nezavist SDD, Placebo - Healthy, Safety Evaluation of Escalating Doses Phase 1 Terminated 29 2025-02-28 2026-09-08 A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults PF-07314470, Placebo for PF-07314470 - Healthy Phase 1 Terminated 23 2025-02-11 2025-10-22 A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People Mid-dose bid BI 3731579, Placebo-matching BI 3731579, Midazolam - Healthy Phase 1 Terminated 30 2024-12-18 2026-08-10 A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body BI 1839100 (C-14) formulation 1, BI 1839100, BI 1839100 (C-14) formulation 2 - Healthy Phase 1 Terminated 8 2024-09-30 2025-09-23 A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006) MK-6552 - Healthy Phase 1 Terminated 24 2024-09-09 2024-12-04 A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults Delafloxacin, Delafloxacin Powder - Healthy Phase 1 Terminated 16 2024-06-03 2026-09-11 A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems Avenciguat (BI 685509) - Healthy, Liver Diseases Phase 1 Terminated 4 2024-05-03 2025-07-17 Dose-finding PKPD Trial for RE02 in Healthy Subjects RE02, Manitol - Healthy Phase 1 Terminated 4 2023-11-20 2024-11-27 A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults PF-07899895, Placebo - Healthy Phase 1 Terminated 37 2023-11-17 2025-11-25 A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis LY3872386, Prednisone, Placebo - Healthy, Atopic Dermatitis Phase 1 Terminated 18 2023-11-01 2025-10-03 A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Yasmin®, BI 1358894 - Healthy Phase 1 Terminated 29 2023-09-08 2025-02-24 Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose Low dose Regular Insulin, High dose Regular insulin - Healthy Phase 1 Terminated 2 2023-08-16 2025-11-18 A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants Dabigatran etexilate (DE), Rosuvastatin, PF-07081532 - Healthy Phase 1 Terminated 16 2023-03-27 2024-11-15
Showing 20 of 189. Sign in to see all of them.
Narrower conditions Asthma (3) · Dermatitis, Atopic (3) · Parkinson Disease (2) · Renal Insufficiency (2) · Schizophrenia (2) · Acquired Immunodeficiency Syndrome (1) · Alzheimer Disease (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Cognitive Dysfunction (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Diabetes Mellitus, Type 2 (1) · Fasting (1)
Broader conditions Immune System Diseases (10) · Pathological Conditions, Signs and Symptoms (8) · Hypersensitivity, Immediate (6) · Nervous System Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hypersensitivity (5) · Pathologic Processes (5) · Skin and Connective Tissue Diseases (5) · Chronic Disease (4) · Digestive System Diseases (4) · Disease Attributes (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Nutritional and Metabolic Diseases (4)
Interventions Midazolam (6) · Buprenorphine (4) · Itraconazole (3) · Ketamine (3) · Sodium Chloride (3) · Amodiaquine (2) · Artemether, Lumefantrine Drug Combination (2) · Carbon-14 (2) · Dabigatran (2) · Lansoprazole (2) · Omeprazole (2) · Ritonavir (2) · Tablets (2) · deleobuvir (2) · drospirenone and ethinyl estradiol combination (2)
Sponsors Boehringer Ingelheim (34) · Pfizer (24) · Eli Lilly and Company (14) · Janssen Research & Development, LLC (12) · AstraZeneca (11) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · H. Lundbeck A/S (5) · Grünenthal GmbH (4) · Alexion Pharmaceuticals, Inc. (3) · John Sundy (3) · National Institute of Mental Health (NIMH) (3) · Biogen (2) · Genmedica Therapeutics S.L. (2) · Janssen Pharmaceutica N.V., Belgium (2) · Janssen Pharmaceutical K.K. (2)
Countries United States (74) · Germany (22) · United Kingdom (19) · Belgium (15) · Netherlands (12) · Japan (8) · France (5) · Singapore (5) · New Zealand (4) · Spain (3) · Sweden (3) · Australia (2) · Austria (2) · Canada (2) · Israel (2)
Top investigators Carin Jorup (2) · Masahiro Fujita, M.D. (2) · Wolfgang Timmer, Dr. (2) · Adeep Puri, MD (1) · Albena Patroneva, MD (1) · Alexandra B. Kimball, MD, MPH (1)
Results publications PMID 24669829 , PMID 39175217 , PMID 10364418 , PMID 11412143 , PMID 11782649 , PMID 11838581 , PMID 15051858 , PMID 15879163 , PMID 21782874 , PMID 23171069 , PMID 24126931 , PMID 26605514 , PMID 30623096 , PMID 31320290 , PMID 32055822 , PMID 35449322 , PMID 36630958 , PMID 37584365 , PMID 38294091 , PMID 38854091 , PMID 39654356 , PMID 41459594 , PMID 42053447 , PMID 42684025 , PMID 8568662 , PMID 9279815
NIH funding 2019 (8) , 2018 (7) , 2017 (6) , 2015 (3) , 2016 (3) , 2009 (2) , 2014 (2) , 2023 (1) , 2025 (1) , R01DA003890 (1) , R21HD054697 (1) , R44AA024905 (1) , U19AI103461 (1) , U54HL117798 (1)